Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2018 May 15;104(6):1175–1181. doi: 10.1002/cpt.1093

Figure 4.

Figure 4

Regulatory applications (INDs) with FDA- generated documents in the DARRTS database that referred to KIM-1 as a drug development tool, grouped by study type: rats, nonclinical (excluding rats), and clinical. Please note that a single regulatory document may contain multiple uses of KIM-1 (for example, use of KIM-1 in the nonclinical as well as clinical studies).